Sleep Disorders
Alkermes Pushes Narcolepsy Program to Phase III With Highly Competitive Mid-Stage Data
Alkermes; alixorexton; narcolepsy; Phase II trial; Phase III clinical trial; orexin 2 receptor agonist; wakefulness; sleep disorder; clinical endpoints